Early Treatment With Oral Fluvoxamine, Inhaled Budesonide Reduces Risk Of Severe COVID-19, Research Suggests

Healio (4/19, Bascom) reports, “Early treatment with oral fluvoxamine plus inhaled budesonide reduced the incidence of progression to severe disease among high-risk outpatients with COVID-19, according to research.” The findings were published in the Anna...